Search Results 721-730 of 18943 for Neutrophil

  1. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  2. Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery - Mayo Clinic

    The following laboratory values obtained ≤14 days prior to registration. Absolute neutrophil count (ANC) ≥1200/mm3; Peripheral Platelet Count (PLT) ...

  3. ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection - Mayo Clinic

    Absolute neutrophil count of <500 cells/ml3; Major gastrointestinal surgery (e.g. significant bowel resection or diversion) within 3 months before enrollment ...

  4. Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1000/mm^3;; Platelet count ≥ 75,000/mm^3*;; Hemoglobin ≥ 9.0 g/dL;; Total bilirubin ≤ 1.5 X upper limit of normal (ULN); ...

  5. Rituximab Vasculitis Maintenance Study - Clinical Trials

    Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in ...

  6. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a neutrophil ...

  7. LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma - Mayo Clinic

    No cytopenias - absolute neutrophil count (ANC) < 1000 or platelets < 100,000 ... No evidence of myelodysplasia. Eastern Cooperative Oncology Group (ECOG) ...

  8. Clinical trials - Oncology (Medical)

    MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) ...

  9. Clinical trials - Oncology (Medical)

    MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) ...

  10. Clinical trials - Oncology (Medical)

    MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) ...